|
|
Biomarin Pharmaceutical Inc (BMRN) |
|
|
|
Biomarin Pharmaceutical Inc's Yearly Income from Continued Operations Growth 5 Years |
|
Select the Comparisons :
|
|
Select the Ratio:
|
Annual Income from Cont. Operations Annual Growth Rates Y/Y▼
|
Annual Income from Cont. Operations Annual Growth Rates Y/Y▼
|
BMRN Annual Income from Cont. Operations Growth |
2023
|
2022
|
2021
|
2020
|
2019
|
Y / Y Annual Income from Cont. Operations Change |
18.43 % |
- |
- |
- |
- |
Annual Income from Cont. Operations (in millions $) |
$167.65 |
$141.56 |
$-64.08 |
$859.10 |
$-23.85 |
Annual Income from Cont. Operations Growth
Comment |
Biomarin Pharmaceutical Inc's Annual Income from Cont. Operations for the fiscal year ended 2023, grew by 18.43% to $167.65 millions, from $141.56 millions achieved a year ago. Biomarin Pharmaceutical Inc's growrh rate for Income from Continued Operations improved from -320.91 % decline in the fiscal year 2022.
Biomarin Pharmaceutical Inc Annual Income Statement
|
You need to upgrade your Flash Player
|
| |